There are unconfirmed rumours from as close as Australia that vaccinated covid-19 patients are being treated with ivermectin (which is banned in Australia) while the unvaccinated are being put on ventilators.
There are many reliable reports that people are being “diagnosed” with covid-19 and put on a combination of respirator, remdesivir and midazolam.
From the UK
Midazolam was used to prematurely end the lives of thousands who you were told had died of Covid-19 and we can prove it; here’s the evidence…
There have not been an reports that this happening in New Zealand – yet.
But by joining a few dots one can see that it MIGHT become a reality.
There seems, now to be both means and opportunity.
Firstly, hear what Ashley Bloomfield has to say about the simple remedies for a disease that is more akin to a serious flu than the Black Death it is being described as.
Last year the drug of choice for killing patients, remdesivir although not approved for use in New Zealand by Medsafe is being imported.
What we’re doing
We have secured additional stock of remdesivir (Veklury) for the treatment of patients hospitalised with moderate to severe COVID-19 subject to inclusion and exclusion criteria.
Detail about this decision
In August 2020 Pharmac entered into an agreement with Gilead Sciences, Australia & New Zealand (Gilead) for the supply of a limited quantity of remdesivir (Veklury) for the treatment of patients hospitalised with moderate to severe COVID-19. This stock has now been exhausted.
As a result of the current COVID-19 delta variant outbreak in New Zealand, and to prepare for future COVID-19 outbreaks, Pharmac has secured further supply of remdesivir for use in New Zealand. Remdesivir will not be listed on the Pharmaceutical Schedule; however, it will be available for DHB Hospitals to order via pharmaceutical wholesaler Onelink.
Remdesivir is not approved by Medsafe for use in New Zealand, meaning it would continue to be prescribed and used in accordance with section 25 of the Medicines Act 1981(external link).
The prescribing clinician is required to review the following inclusion and exclusion criteria, which have been adopted and adapted from the current Australian Government’s criteria for access (as of 14 October 2020).
Funded access to remdesivir is available for the treatment of moderate to severe COVID-19 in patients who satisfy all of the following inclusion and exclusion criteria, and special considerations:
- age ≥ 18 years, or aged ≥ 12 and < 18 years of age weighing ≥ 40 kg.
- is hospitalised with confirmed SARS-CoV2 or known contact of confirmed case with syndrome consistent with coronavirus disease (COVID-19) awaiting confirmation by diagnostic testing.
- has oxygen saturation (SpO2) ≤ 92% on room air and requiring supplemental oxygen
- has alanine aminotransferase (ALT) < 5 x upper limit of normal (ULN) by local laboratory measure; and/or ALT < 3 x ULN and bilirubin < 2 x ULN.
- The treating clinicians consider that such escalation of care is appropriate.
- Informed consent has been provided by the patient or the patient’s legal representative, according to local practices.
- has evidence of multiorgan failure including but not limited to coagulopathy (significant thrombocytopenia), hepatic failure (elevated bilirubin) or renal failure (low urine output or estimated glomerular filtration rate (eGFR) less than 30 mL/min), or significant cardiomyopathy (low cardiac output).
- has renal failure (eGFR less than 30 mL/min or dialysis or continuous venovenous haemofiltration.
- has been on mechanical ventilation for longer than 48 hours at time of application
- is receiving ECMO.
- has known hypersensitivity to remdesivir, the metabolites, or formulation excipient.
The clinical benefit of remdesivir is uncertain in some scenarios. The prescribing clinician should give strong consideration to whether remdesivir is likely to benefit the patient in the following scenarios:
- Mechanical ventilation for less than 48 hours at time of commencing treatment with remdesivir
- Presence of an intercurrent illness which is likely to lead to the patient’s death within one year
- Advanced age with limitations on activities of daily living
- Need for more than a 5 day treatment course.
Further context and review of evidence can be found in the record of the Pharmac ad hoc Remdesivir COVID-19 Advisory Group (September 2020) [PDF, 125 KB].
Accessing supply of remdesivir
DHB hospitals will order stock direct from Onelink. Wholesale stock will be held and distributed to DHB Hospitals by Onelink in Auckland and Dunedin.
For more information, such as dosage and method of administration, please refer to the factsheet provided by Gilead Sciences (New Zealand) [PDF, 975 KB].
- August 2021 Remdesivir Factsheet [PDF 975 KB]
- September 2021 Remdesivir treatment notification form [DOCX 37 KB]
Radio New Zealand wrote a informational article (ie. propaganda) for remisdevir. It is interesting to see how the article refers to Australia but fails to point out that it has been approved for use in New Zealand (shown by the article above and the absence of anything on an internet search)
By Belinda Smith
Australian doctors recently added another drug to their repertoire of Covid-19 treatments – one that stimulates the body’s immune system to intercept and destroy the virus.
The drug, called sotrovimab, is an addition to a handful of green-lit treatments, most of which help calm inflammation caused by the immune system’s overreaction to the virus.
But only one approved drug, remdesivir, interrupts a virus’s rampage within our cells, where millions of copies of the virus are made and sent out to infect more cells – and people.
So why is it so hard to break the lifecycle of viruses such as SARS-CoV-2, which causes Covid-19 disease?
In a way, Covid-19 is a disease of two stages, says Raymond Schinazi, who develops antiviral drugs at Emory University.
During the first stage of the disease, the virus makes copies of itself in your body, often without producing symptoms.
In the second, your body’s immune system kicks in. For some people, this progresses to severe disease as their immune system attacks organs and causes inflammation.
The idea of treating the early stage of the infection with antivirals is to stop people from progressing to the point where severe disease sets in.
But remdesivir, the only direct-acting antiviral approved for use in Covid-19 in Australia, isn’t spectacular, says Sharon Lewin, an infectious disease researcher and director of the Doherty Institute.
“It gives you a little bit of time, it reduces your time in hospital and may potentially have a small mortality benefit, but it’s not dramatic.”
Here is the next ingredient in the deadly cocktail.
Read about midazolam HERE
Reading between the lines I would say that they have adequate supplies of the drug.
Baxter’s brand of Midazolam (Midazolam-Claris) 1mg per ml, 5mg injection was out of stock from 28 February 2021 to early June 2021.
Update 9 June 2021
We understand that the stock has arrived and been released. Talk to your wholesaler about when Baxter-Midazolam will be available.
The delisting date for the Mylan product is likely to be 1 January 2022.
The out of stock was caused by the current stock expiring at the end of February and Baxter’s replacement brand Midazolam-Baxter not yet being available.
To ensure continuity of supply, an alternative brand of Midazolam supplied by Mylan was listed in the Community Pharmaceutical Schedule from 1 February 2021. (It was already listed in the HML)
Details of the alternative product are as follows:
- Chemical and presentation: Midazolam inj 1 mg per ml, 5 ml ampoule
- Brand: Mylan Midazolam
- Pack Size: 10
- Subsidy and price (ex-man., ex. GST): $2.98
- Pharmacode: 2474468
RxOne users: the new listings and changes will be automatically updated by RxOne. If for some unforeseen circumstance it does not happen, please refer to the e-Noticeboard on the RxOne Home Screen for instructions.
TONIQ users: the new listings and changes will automatically be updated in Toniq medicine databases from the effective date.
Please note that Ministry of Health Sector Operations Group will be able to process claims for February 2021 dispensing of the above listing.
The other essential agreement is ventilation. The following article shows that most covid patients on ventilators died.
The following shows the capacity for ventilators in New Zealand.